HtrA3:一个有前途的预后生物标志物和治疗目标,用于头部和部状细胞癌

相关实验视频

Updated: Jul 13, 2025

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

Yan Chen^1,2,3, Jianfeng Yang^1,2,3, Hangbin Jin^1,2,3

¹Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.

|October 16, 2023

概括

高温要求的A (HtrA) 蛋白酶在头部和部状细胞癌 (HNSCC) 中被上调. HtrA3显示出作为HNSCC.的预后标志物和治疗点的潜力.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

人类高温要求的A (HtrA) 血清蛋白酶的失调与各种癌症有关.
有限的研究存在于HtrA家族成员在头部和部状细胞癌 (HNSCC).

研究的目的:

为了研究HNSCC中的HtrA蛋白酶的表达模式.
评估HtrAs在HNSCC患者的预后意义.
探索HtrA在HNSCC进展中的生物功能.

主要方法:

利用癌症基因组图集 (TCGA) 和基因表达总汇 (GEO) 数据库进行RNA测序和临床数据分析.
进行了差异表达分析,生存分析,基因本体学 (GO),基因和基因组的京都百科全书 (KEGG) 和基因组丰富分析 (GSEA).
通过RT-PCR和Western blot验证了HtrA表达,并使用体外分析研究了HNSCC细胞系上的HtrA3倒置效应.

主要成果:

在HNSCC中,HtrA基因表达显著上调,与年龄,TNM阶段和TP53突变状态等临床参数相关.
提高HtrA1/3的表达与较差的生存结果有关 (总体生存,无进展间隔,疾病特异性生存).
HtrA表达与免疫细胞透 (B细胞,M细胞,DC细胞) 和免疫检查点 (CD276,TNFRSF14) 相关联;HtrA3敲击抑制了HNSCC细胞的增殖和诱导的细胞亡.

结论:

在HNSCC中,HtrA蛋白酶,特别是HtrA3,显著失调.
HtrA3显示出作为HNSCC的预后生物标志物的潜力.
在HNSCC治疗中,HtrA3是一个有前途的治疗标.

关键词:

头部和部状细胞癌瘤这就是HtrA.免疫系统的透.免疫治疗是一种免疫疗法.预测预后预测预测

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Three-Dimensional 3D Tumor Spheroid Invasion Assay

Published on: May 1, 2015

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...